Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NTRA
HoldPremium GrowerNatera, Inc. · Healthcare · United States · $47.0B · Avg Vol: $435M/d
COMPANY DESCRIPTION
Natera, Inc. is a leading diagnostic company focused on cell-free DNA testing for reproductive health, oncology, and organ transplantation. The company's proprietary technology platforms, including Panorama for non-invasive prenatal testing and Signatera for molecular residual disease detection, establish a significant competitive moat in precision medicine. Its commitment to R&D and clinical validation drives its rapid growth and market leadership in targeted diagnostic areas.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 820.2M | 1.1B | 1.7B | 2.3B | 41.1% | 2.7B | 2.9B | 3.5B | 23.0% |
| EPS | -5.57 | -3.78 | -1.53 | -1.52 | — | -1.34 | -1.39 | -0.10 | — |
| Shares | 111.3M | 119.6M | 132.6M | 139.7M | +25.6% | 144.1M | — | — | — |
| Debt | 446.2M | 442.0M | 187.1M | 214.4M | -21.7% | 238.5M | — | — | — |
| Equity | 705.7M | 765.3M | 1.2B | 1.7B | 34.4% | — | — | — | — |
| Op CF | -431.5M | -247.0M | 135.7M | 215.3M | 58.7% | 228.2M | — | — | — |
| Inv CF | 330.3M | 168.5M | 137.6M | -132.2M | — | — | — | — | — |
| Fin CF | 482.6M | 254.5M | 30.2M | 47.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NTRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NTRA | Natera, Inc.(you) | $47.0B | 56 | Hold |
| IDXX | IDEXX Laboratories, Inc. | $43.7B | 58 | Hold |
| WAT | Waters Corporation | $40.7B | 62 | Hold |
| IQV | IQVIA Holdings Inc. | $43.1B | 73 | Buy |
| A | Agilent Technologies, Inc. | $43.4B | 75 | Buy |
| ILMN | Illumina, Inc. | $32.6B | 75 | Buy |
| DHR | Danaher Corporation | $151.9B | 59 | Hold |
| GH | Guardant Health, Inc. | $21.7B | 42 | Hold |
| CRL | Charles River Laboratories International, Inc. | $14.0B | 63 | Hold |
| RVTY | Revvity, Inc. | $14.4B | 64 | Hold |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.1%